Current through Register Vol. 46, No. 12, March 20, 2024
(a)
Applicability.
This section shall apply only to the extent that the
applicable provisions in Education Law sections 6801 and 6801-a, authorizing
certain pharmacists to participate in collaborative drug therapy management,
have not expired or been repealed.
(b)
Definitions.
As used in this section:
(1)
Board means the State
Board of Pharmacy as established by section
6804 of the Education Law.
(2)
Clinical services means
the collection and interpretation of patient data for the purpose of
initiating, modifying and monitoring drug therapy with associated
accountability and responsibility for outcomes in a direct patient care
setting.
(3)
Collaborative
drug therapy management means the performance of clinical services by
a pharmacist relating to the review, evaluation and management of drug therapy
to a patient, who is being treated by a physician for a specific disease or
associated disease states, in accordance with a written agreement or protocol
with a voluntarily participating physician and in accordance with the policies,
procedures, and protocols of the facility.
(4)
Facility means:
(i) a teaching hospital or general hospital,
including any diagnostic center, treatment center, or hospital-based
out-patient department as defined in section
2801 of the Public Health Law; or
(ii) a nursing home with an on-site pharmacy
staffed by a licensed pharmacist; provided, however, for the purposes of this
section the term facility shall not include dental clinics, dental
dispensaries, residential health care facilities and rehabilitation
centers.
(5)
Teaching hospital means a hospital licensed pursuant to
article 28 of the Public Health Law that is eligible to receive direct or
indirect graduate medical education payments pursuant to article 28 of the
Public Health Law.
(6)
Physician means the physician selected by or assigned to a
patient, who has primary responsibility for the treatment and care of the
patient for the disease and associated disease states that are the subject of
the collaborative drug therapy management.
(7)
Written agreement or
protocol means a written document, pursuant to and consistent
with an applicable State or Federal requirements, that addresses a specific
disease or associated disease states and that describes the nature and scope of
collaborative drug therapy management to be undertaken by the pharmacists, in
collaboration with the participating physician in accordance with the
requirements of this section.
(c)
Requirements.
A pharmacist seeking to engage in collaborative drug
therapy management shall submit his or her credentials, in a form determined by
the department, to the department for review. Those pharmacists who the
department determines to meet the requirements of paragraph (3) of this
subdivision and who are employed by or otherwise affiliated with a facility
shall be permitted to enter into a written agreement or protocol with a
physician authorizing collaborative drug therapy management, subject to the
limitations set forth in this section, within the scope of such employment or
affiliation, and shall be identified as being so authorized by a designation
determined by the department.
(1) As
used in section
6801-a(2)(b) of the
Education Law, a year of experience shall mean not less than
1,680 hours of work as a pharmacist within a period of one calendar
year.
(2) In order to be counted as
a year of experience that includes clinical experience in a health facility,
such experience shall include, on average, not less than 15 hours per week of
clinical experience which involves consultation with physicians with respect to
drug therapy, as determined by the facility with which the pharmacist is
employed or affiliated.
(3) A
participating pharmacist shall:
(i)
(a) have been awarded either a master of
science in clinical pharmacy or a doctor of pharmacy degree;
(b) maintain a current unrestricted license;
and
(c) have a minimum of two
years' experience, of which at least one year of such experience shall include
clinical experience in a health facility, which involves consultation with
physicians with respect to drug therapy and may include a residency at a
facility involving such consultation, and such clinical experience shall be
gained within the three years immediately preceding the pharmacist' submission
of his or her credentials to the department for review; or
(ii)
(a)
have been awarded a bachelor of science in pharmacy;
(b) maintain a current unrestricted license;
and
(c) within the last seven
years, have a minimum of three years' experience, of which at least one year of
such experience shall include clinical experience in a health facility, which
involves consultation with physicians with respect to drug therapy and may
include a residency at a facility involving such consultation, and such
clinical experience shall be gained within the three years immediately
preceding the pharmacist' submission of his or her credentials to the
department for review; and
(iii)
(a)
have residency training in a program accredited or accreditation-pending by a
nationally recognized accreditation body acceptable the department;
or
(b) have board certification
awarded by a certification body acceptable to the department and shall include
baseline and ongoing competency assessments; and
(iv) meet additional experience provisions as
follows:
(a) for pharmacists seeking to engage
in collaborative drug therapy management by satisfying the requirements of
clauses (i)(a) though (c) of this paragraph,
if he or she seeks to utilize residency training to satisfy the one year of
clinical experience requirement, the second year of required experience shall
also be clinical experience, unless such pharmacist possesses board
certification that satisfies the requirements of clause
(iii)(b) of this paragraph.
(b) for pharmacists seeking to engage in
collaborative drug therapy by satisfying the requirements of clauses
(ii)(a) through (c) of this paragraph, if he
or she seeks to utilize residency training to satisfy the one year of clinical
experience requirement, an additional year' experience of the three years
required shall also be clinical experience, unless such pharmacist possesses
board certification that satisfies the requirements of clause
(iii)(b) of this paragraph.
(d)
Requirements for
collaborative drug therapy management written agreements or protocols.
A physician who is a party to a written agreement or
protocol to authorize collaborative drug treatment shall be employed by or
otherwise affiliated with the same facility with which the pharmacist is also
employed or affiliated and their written agreement or protocol may include, and
shall be limited to, the following:
(1)
adjusting or managing a drug regimen of a patient, pursuant to a patient
specific order or protocol made by the patient' physician, which may include
adjusting drug strength, frequency of administration or route of
administration. Adjusting the drug regimen shall not include substituting or
selecting a different drug which differs from that initially prescribed by the
patient' physician unless such substitution is expressly authorized in the
written order or protocol. The pharmacist shall be required to immediately
document in the patient' medical record changes made to the patient's drug
therapy and shall use any reasonable means or method established by the
facility to notify the patient's other treating physicians with whom he or she
does not have a written agreement or protocol regarding such changes. The
patient's physician may prohibit, by written instruction, any adjustment or
change in the patient's drug regiment by the pharmacist;
(2) evaluating and, only if specifically
authorized by the protocol and only to the extent necessary to discharge the
responsibilities set forth in this section, ordering disease State laboratory
tests related to the drug therapy management for the specific disease or
disease state specified within the written agreement or protocol; and
(3) only if specifically authorized by the
written agreement or protocol and only to the extent necessary to discharge the
responsibilities set forth in this section, ordering or performing routine
patient monitoring functions as may be necessary in the drug therapy
management, including the collecting and reviewing of patient histories, and
ordering or checking patient vital signs, including pulse, temperature, blood
pressure and respiration.
(e)
Additional provisions relating to
collaborative drug therapy management written agreements and protocols.
(1) The existence of a written agreement or
protocol on collaborative drug therapy management and the patient's right to
choose to not participate in collaborative drug therapy management shall be
disclosed to any patient who is eligible to receive collaborative drug therapy
management. Collaborative drug therapy management shall not be utilized unless
the patient or the patient's authorized representative consents, in writing, to
such management. If the patient or the patient's authorized representative
consents, it shall be noted on the patient's medical record. If the patient or
the patient's authorized representative who consented to collaborative drug
therapy management chooses to no longer participate in such management, at any
time, it shall be noted in the patient's medical record. In addition, the
existence of the written agreement or protocol and the patient's consent to
such management shall be disclosed to the patient's primary care physician and
any other treating physician or healthcare provider.
(2) Participation in a written agreement or
protocol authorizing collaborative drug therapy management shall be voluntary,
and no patient, physician, pharmacist, or facility shall be required to
participate.